Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.

Kaklamani, Virginia G; Richardson, Andrea L; Arteaga, Carlos L

Kaklamani, Virginia G; Richardson, Andrea L; Arteaga, Carlos L.

Affiliation

Kaklamani VG; University of Texas Health Science Center, San Antonio, Texas, USA kaklamani@uthsca.edu.
Richardson AL; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Arteaga CL; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Oncologist ; 24(3): 305-312, 2019 03.

Article in En | MEDLINE | ID: mdl-30651399

Subject(s)

Breast Neoplasms/drug therapy; Breast Neoplasms/genetics; Phosphatidylinositol 3-Kinases/genetics; Receptor, ErbB-2/genetics; Biomarkers, Tumor/genetics; Breast Neoplasms/pathology; Female; Humans

Key words

Alpelisib; Breast neoplasms; Buparlisib; Molecular targeted therapy; PIK3CA protein, human; Taselisib

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Phosphatidylinositol 3-Kinases Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2019 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google